SEP 10, 2026 · JOURNAL ARTICLE
Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy
Nature Communications
This is preclinical target discovery and validation work using in vitro and animal models; it establishes MPZL1 as a candidate CAR-T target but does not present clinical efficacy data or human trials.
Reported
MPZL1 amplification frequencyup to 75%